In Practise Logo
In Practise Logo - Blue
In Practise Logo
IP Interview
Published September 23, 2024

Bonesupport: History, Competition & Market Size

Executive Bio

Former Senior Sales Executive at Bonesupport

Interview Transcript

Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.

This is a snippet of the transcript.to get full access.

It's only $5,000 in the US, for CERAMENT G?

And in a very average hospital like Syracuse, there's a hospital there called Community General. There are 10 orthopedic surgeons there. Five of them or four of them will use it. All of a sudden, each doctor is doing 50 kits at $5,000, giving us $250,000 per doctor. And now I have five or four doctors. Every regional hospital in some town, USA, is worth $1 million. And what do I take into the account? Nothing. No kit, no hardware, no trials, nothing. No instrumentation. Zero. Just the CERAMENT kit, which is a small box. They open it, they inject it. And furthermore, you don't need to stay there for the entire procedure. You can just be there for 30 minutes and be gone.

This is a snippet of the transcript.to get full access.

So the bone growth is really the big differentiator between BONESUPPORT and its competitors.

When I left, we were the top contender at the British Foot and Ankle Society meeting. Doctors would flock to us. Our dinners had 20 doctors every night, not drinking wine, but really chatting about the science and engaging with other doctors. What is the most important indication for trauma based on amputations? Who are half of all patients that get an amputation foot.

This is a snippet of the transcript.to get full access.

Free Sample of 50+ Interviews

Sign up to test our content quality with a free sample of 50+ interviews.

Or contact sales for full access

© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.